세계 분자 이미징 시장 규모는 2024년 79억 6,000만 달러에서 2033년까지 123억 6,000만 달러에 달할 것으로 예상되며, 2025-2033년 CAGR 5.01%로 성장할 것으로 예상됩니다. 이는 질병의 조기 진단에 대한 수요 증가, 영상 진단법의 기술 혁신, 분자 영상이 정밀 진단 및 맞춤 치료에 중요한 역할을 하는 암 및 신경 질환의 발병률 증가 등에 기인합니다.
분자 이미징 시장 성장 촉진요인
만성질환 유병률 증가
암, 심혈관질환, 신경질환과 같은 만성질환의 유병률 증가는 분자 이미징 산업의 주요 촉진요인입니다. 이러한 질병은 조기에 정확한 진단이 필요한데, 분자 이미징은 분자 및 세포 수준에서 생물학적 기능을 시각화하여 이를 가능하게 합니다. 이러한 기능을 통해 질병의 발견, 병기 분류 및 모니터링이 개선되고, 환자 예후가 개선되어 차세대 이미징 기술에 대한 수요가 증가하고 있습니다. 매년 1,800만 명이 심장과 혈관을 침범하여 심장마비, 뇌졸중, 심부전을 유발하는 심혈관질환으로 목숨을 잃습니다. 암으로 인한 사망자는 연간 약 900만 명, 천식, COPD 등 만성 호흡기질환으로 인한 사망자는 400만 명, 당뇨병으로 인한 사망자는 200만 명입니다. 그러나 질병 부담과 현대 의료에 대한 접근성은 불균형적으로 배분되고 있습니다.
영상 진단의 발전
PET/CT, PET/MRI와 같은 하이브리드 영상 진단법의 도입으로 영상 진단법의 지속적인 발전은 진단의 가능성을 바꿔놓았습니다. 이러한 발전은 더 높은 해상도의 영상을 얻을 수 있고, 민감도가 향상되어 질병을 조기에 발견할 수 있는 가능성을 열어주었습니다. 이러한 기술의 발전은 진단 정확도를 향상시킬 뿐만 아니라 맞춤형 의료에서 분자 이미징의 활용도를 높여 시장 성장을 촉진하고 있으며, 2024년 6월, Lantheus Holdings, Inc. Molecular Imaging의 가스트린 방출 펩타이드 수용체(GRPR)를 표적으로 하는 RM2에 대한 전 세계 판권을 취득했다고 보고했습니다. 여기에는 임상 단계의 방사선 치료제 177Lu-DOTA-RM2와 방사선 진단제 68Ga-DOTA-RM2가 포함됩니다. 이번 인수를 통해 Lantheus는 전립선암에 중점을 둔 파이프라인을 유방암 및 기타 암으로 확장할 예정이며, 계약금 3,500만 달러와 마일스톤 및 로열티가 지급될 수 있습니다.
연구 개발의 혁신
새로운 조영제를 발굴하고, 기존 이미징 기법을 강화하기 위한 연구개발 과정에 많은 투자가 이루어지고 있습니다. 이는 보다 효율적인 진단 및 치료법 개발로 이어질 수 있기 때문에 분자 이미징의 발전에 필수적입니다. 미국 방사선학회(America College of Radiology)에 따르면, 대통령의 2024년 예산안에는 국립암연구소(National Cancer Institute, NCI)에 대한 재량권 예산이 대폭 증가했다고 합니다.에 대한 재량 예산이 대폭 증액되어 2023년 예산보다 5억 달러가 증가한 7억 1,600만 달러가 책정되었습니다. 이 자금은 연구, 예방, 진단 및 치료 노력을 촉진하는 데 사용되며, 이 모든 것은 방사선학 및 영상 기술에 크게 의존하고 있습니다.
분자 이미징 시장의 과제
이미징 장비 및 시술의 높은 비용
첨단 분자 이미징 장비와 시술의 높은 비용은 시장 확대에 큰 걸림돌로 작용하고 있습니다. 특히 개발도상국이나 소규모 의료센터에서는 높은 취득 및 유지비용이 이러한 기술의 사용을 제한하고 있습니다. 또한, 조영제 비용과 숙련된 인력의 필요성도 경영비용을 증가시켜 보급을 저해하고 있습니다.
규제와 상환의 과제
분자 이미징 시술의 복잡한 규제 환경에 대응하고 보험급여를 획득하는 것은 여전히 어려운 과제입니다. 까다로운 규제 환경은 새로운 조영제 및 장비의 승인과 상용화를 방해할 수 있습니다. 또한, 지역별로 상이한 상환 정책은 분자 이미징 서비스의 가용성과 비용에 영향을 미쳐 시장 침투에 영향을 미칠 수 있습니다.
세계의 분자 이미징 시장에 대해 조사했으며, 성장 촉진요인 및 과제, 각 부문별 분석, 주요 기업 분석 등의 정보를 전해드립니다.
The Molecular Imaging Market is anticipated to grow to US$ 12.36 billion by 2033 from US$ 7.96 billion in 2024, at a CAGR of 5.01% during the period from 2025 to 2033. This is fueled by increasing demand for early disease diagnosis, technological innovations in imaging modalities, and rising incidence of cancer and neurological diseases, where molecular imaging plays a critical role in precision diagnosis and personalized treatment.
The report Molecular Imaging Market & Forecast covers by Modality (Single Photon Emission Computed Tomography, Psitron Emmission Tomography, Nuclear Magnetic Resonance Spectrometer, Molecular Ultrasound Imaging, Others), Application (Oncology, Cardiovascular, Neurology, Respiratory, Gastrointestinal), End Use (Hospitals, Diagnostic Imaging Centers, Research Institutes), Country and Company 2025-2033.
Molecular Imaging Market Outlooks
Molecular imaging is a cutting-edge biomedical technology that facilitates visualization, characterization, and measurement of biological functions at the molecular and cellular level within living systems. In contrast to conventional imaging technologies that merely concentrate on anatomical structures, molecular imaging yields extensive information regarding how tissues and organs work in real-time. It integrates imaging modalities like positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and optical imaging with molecular probes or biomarkers.
Molecular imaging is essential in the early disease detection and follow-up of conditions like cancer, cardiovascular disease, and neurological diseases like Alzheimer's and Parkinson's disease. It assists in assessing the effectiveness of a treatment by monitoring biological reactions at the molecular level. It also assists in drug discovery since researchers can monitor how new drugs interact with biological targets in living organisms. Its non-invasive character and capability to deliver accurate, functional information make molecular imaging a pillar of personalized medicine.
Growth Drivers in the Molecular Imaging Market
Increased Incidence of Chronic Diseases
The growing prevalence of chronic diseases like cancer, cardiovascular disease, and neurological conditions is a key growth driver for the molecular imaging industry. Such diseases require early and precise diagnosis, which molecular imaging makes possible through the visualization of biological functions at the molecular and cellular levels. Such a capability improves the detection, staging, and monitoring of disease, improving patient outcomes and driving demand for next-generation imaging technology. Every year 18 million individuals succumb to cardiovascular diseases that involve the heart and blood vessels and can result in heart attacks, stroke, or heart failure. Approximately 9 million individuals die annually from cancers, 4 million from chronic respiratory diseases like asthma or COPD, and 2 million from diabetes. But both disease burden and access to contemporary health care are disproportionately allocated.
Advances in Imaging Modalities
Ongoing advances in imaging modalities, with the introduction of hybrid imaging modalities such as PET/CT and PET/MRI, have transformed diagnostic potential. These advances provide images with greater resolution, increased sensitivity, and the potential to detect illnesses at earlier stages. These technological advances not only improve diagnostic precision but also increase the utilization of molecular imaging in personalized medicine, thus boosting market growth. June 2024, Lantheus Holdings, Inc. reported its acquisition of worldwide rights to Life Molecular Imaging's RM2, targeting the gastrin-releasing peptide receptor (GRPR). These include the clinical-stage radiotherapeutic 177Lu-DOTA-RM2 and the radiodiagnostic 68Ga-DOTA-RM2. The acquisition strengthens Lantheus' emphasis on prostate cancer and broadens its pipeline to breast and other cancers, with an upfront payment of $35 million plus possible milestone payments and royalties.
Innovation in Research and Development
Higher expenditure in research and development processes to identify new imaging agents and enhance current imaging methods is underway. It is vital for the development of molecular imaging, as it results in the creation of more efficient diagnostic methods and treatments. The focus on R&D provides a stream of new solutions, which supports growth in the market and fills gaps in clinical need. As per the America College of Radiology, The president's 2024 budget included a substantial increase in discretionary funding for the National Cancer Institute (NCI) to USD 716 million, a USD 500 million increase from the FY 2023 allocation. The funds are to be used to advance research, prevention, diagnosis, and treatment efforts, all of which rely extensively on radiology and imaging technology.
Challenges in the Molecular Imaging Market
High Cost of Imaging Equipment and Procedures
The high cost of advanced molecular imaging equipment and procedures is a major hindrance to market expansion. High acquisition and maintenance expenses restrict the use of these technologies, especially in developing countries and small healthcare centers. The cost of imaging agents and the requirement for skilled personnel also drive up operational costs, preventing widespread adoption.
Regulatory and Reimbursement Challenges
Working with the intricate regulatory environment and gaining reimbursement for molecular imaging procedures is still difficult. The strict regulatory environment can hold up the approval and commercialization of new imaging agents and devices. In addition, variable reimbursement policies between different regions can impact the availability and cost of molecular imaging services, which can influence market penetration.
Molecular Ultrasound Imaging Market
Molecular ultrasound imaging integrates conventional ultrasound methods with targeted contrast agents to image particular molecular markers in the body. Molecular ultrasound imaging is a non-invasive technique with real-time imaging and high spatial resolution, and it is worth its weight in gold for early disease detection and monitoring therapeutic interventions. Its low cost of entry and favorable safety profile over other imaging modalities make it increasingly popular in the clinical environment.
Oncology Molecular Imaging Market
In cancer, molecular imaging is a central component of early detection, staging, and monitoring of cancer. Modalities such as PET and SPECT allow visualization of tumor metabolism and receptor expression and thus insight into tumor biology. Such information is invaluable for choosing the right therapies, evaluating treatment response, and detecting recurrences, thus enhancing patient management and outcomes.
Neurology Molecular Imaging Market
Molecular imaging plays a crucial role in diagnosing and managing neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy. By visualizing distinct neurotransmitter systems and pathological protein accumulations, these imaging techniques enable early diagnosis and monitoring of disease progression. This ability fosters a greater understanding of neurological disease and aids in the creation of targeted therapeutics.
Respiratory Molecular Imaging Market
Molecular imaging is supporting the evaluation of diseases such as chronic obstructive pulmonary disease (COPD), asthma, and lung cancer in respiratory medicine. Molecular imaging helps in imaging inflammatory processes, ventilation-perfusion mismatches, and tumor metabolism. All of this information guides clinicians to tailor treatment regimens, follow the therapeutic responses, and enhance the outcomes of the patients.
Molecular Imaging Hospitals Market
Hospitals are the first adopters of molecular imaging technologies because of their complete diagnostic and therapeutic facilities. Incorporation of molecular imaging in hospitals improves diagnostic accuracy, informs treatment planning, and enables personalized medicine strategies. Multidisciplinary teams and advanced infrastructure available in hospitals enable effective use of these imaging modalities.
Molecular Imaging in Research Institutes
Research institutes utilize molecular imaging to study mechanisms of disease, assess emerging treatments, and generate new imaging probes. The institutes are significant players in expanding the field by engaging in preclinical and clinical investigations that directly guide clinical care. Research institutes working together with industry partners are at the heart of driving innovation and shaping advances in molecular imaging technology.
United States Molecular Imaging Market
The United States is a large market for molecular imaging, with high incidence of chronic diseases, sophisticated healthcare infrastructure, and high research and development investment. The availability of top imaging technology firms and academic institutions encourages innovation and uptake of advanced imaging modalities. Favorable regulatory environments and reimbursement policies also encourage market growth. November 2024, United Imaging installed the world's first uMI Panvivo PET/CT at Pueblo Medical Imaging in Nevada, USA. The next-generation platform boasts a best-in-class NEMA spatial resolution of 2.9 mm* and an effective sensitivity of 181 cps/kBq. Equipped with its AI-based 3D camera technology, the uMI Panvivo brings precision and care to all.
Germany Molecular Imaging Market
Germany's molecular imaging market is marked by strong healthcare infrastructure, high focus on medical research, and positive reimbursement policies. The precision medicine and early disease detection focus of the country facilitates the uptake of advanced imaging technologies. Academic-industry collaborations help in the development and deployment of innovative imaging solutions. United Imaging has deployed its innovative molecular imaging technology in Germany, partnering with Medical Imaging Electronics (MiE). The Kliniken Essen-Mitte Evang and Nukmed are now equipped with the uMI 550 digital PET/CT system, a cutting-edge system.
India Molecular Imaging Market
The molecular imaging market in India is growing, supported by growing healthcare consciousness, rising chronic disease incidence, and increasing investments in healthcare infrastructure. Government policies promoting diagnostic ability and access to advanced medical technologies are driving market expansion. The emergence of affordable imaging solutions optimized for the Indian populace is also driving market growth. May 2025, Mahajan Imaging & Labs has inaugurated North India's first 128-Slice Digital PET-CT - Omni Legend by GE HealthCare, along with a state-of-the-art pathology lab in Gurugram. This new center is a major step forward in integrated cancer care and diagnostics for Delhi NCR.
Saudi Arabia Molecular Imaging Market
Saudi Arabia is experiencing growth in the molecular imaging market because of the increasing burden of chronic diseases, government investment in healthcare modernization, and initiatives to improve diagnostic capabilities. The Vision 2030 initiative of the country focuses on the development of sophisticated healthcare services, including the implementation of cutting-edge imaging technologies. Partnerships with global players and investments in health infrastructure facilitate the growth of the market. December 2024, King Abdulaziz University (KAU) has initiated a groundbreaking Alzheimer's disease diagnosis service at its Molecular Imaging Center (I-One) via Wadi Jeddah. This service is provided using combined Positron Emission Tomography and Magnetic Resonance Imaging (PET/MRI), making it the first of its nature in Saudi Arabia.
Molecular Imaging Market Segmentation
Modality
Application
End Use
Countries
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
All companies have been covered with 4 Viewpoints